Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study - Ebina, K.; Noguchi, T.; Hirao, M.; Hashimoto, J.; Kaneshiro, S.; Yukioka, M.; Yoshikawa, H. (Osteoporosis international, 2016)
Keywords: Absorptiometry, Photon - methods; Adult; Aged; Aged, 80 and over; Alendronate - administration & dosage; Alendronate - therapeutic use; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - physiopathology; Biomarkers - blood; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Bone Remodeling - drug effects; Diphosphonates - administration & dosage; Diphosphonates - therapeutic use; Drug Administration Schedule; Drug Substitution; Drug therapy; Endocrinology; Female; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Medicine; Medicine & Public Health; Middle Aged; Original Article; Orthopedics; Osteoporosis; Osteoporosis, Postmenopausal - drug therapy; Osteoporosis, Postmenopausal - etiology; Osteoporosis, Postmenopausal - physiopathology; Osteoporotic Fractures - etiology; Osteoporotic Fractures - physiopathology; Osteoporotic Fractures - prevention & control; Patient Preference; Prescription drugs; Prospective Studies; Rheumatoid arthritis; Rheumatology; Risedronate Sodium - administration & dosage; Risedronate Sodium - therapeutic use; Risk factors; Risedronate; Osteoporosis; Minodronate; Alendronate; Rheumatoid arthritis